<table>
<thead>
<tr>
<th>Medication [Drug Class]</th>
<th>PREPARATIONS</th>
<th>TYPICAL DOSAGE</th>
<th>ADMINISTRATION NOTES &amp; POTENTIAL ADVERSE EFFECTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amiodarone [antiarrhythmic]</td>
<td>For injection: Nexerone® (amiodarone without preservative) 150 mg (1.5 mg/ml) or 360 mg (1.8 mg/ml) in premixed bags Tablets: 200, 400 mg</td>
<td>Parenteral: 2–5 mg/kg, IV infused over 30 to 60 minutes with careful BP and rhythm monitoring PO: 8–10 mg/kg, q12–24h for 7 to 10 days then reduce to 4–6 mg/kg, q24h chronically</td>
<td>• Do not use amiodarone preserved with polysorbate80 intravenously due to risk of anaphylactoid reaction • Typically not the 1st line therapy • Long elimination half-life • Elevated liver enzymes/hepatotoxicity (common), monitoring recommended • Thyroid dysfunction, blood dyscrasia, proarrhythmia</td>
</tr>
<tr>
<td>Amlodipine* [arterial dilator]</td>
<td>Tablets: 2.5, 5, 10 mg</td>
<td>PO: 0.1–0.2 mg/kg, q12h or 0.2–0.4 mg/kg, q24h</td>
<td>• Up-titration of dose to desired BP effect • In resistant systemic hypertension, doses at the higher end of the dosage range are needed • In CHF, initial dosages should be at the lower end of the range • Hypotension, RAAS activation, gingival hyperplasia</td>
</tr>
<tr>
<td>Atenolol* [beta–blocker]</td>
<td>Tablets: 25, 50, 100 mg</td>
<td>PO: 0.2–1.0 mg/kg, q12h</td>
<td>• Gradual up-titration required, especially in CHF or DCM • Dogs without CHF can tolerate higher initial and target dosages • Gradual up-titration required, especially in CHF • Abrupt discontinuation should be avoided, gradual down-titration is recommended • Myocardial depression, bradycardia (sinus and AVB), hypotension</td>
</tr>
<tr>
<td>Atropine [anticholinergic]</td>
<td>For Injection: 0.05, 0.1, 0.4, 1.0 mg/ml as well as other concentrations (USP)</td>
<td>Parenteral (single) doses: 0.05 to 0.2 mg/kg, IV 0.2–0.4 mg/kg, IM or SQ</td>
<td>• Intravenous administration can lead to (initial paradoxical) AVB • Sinus tachycardia, increased risk of ventricular ectopy • Drying of respiratory secretions, reduced GI motility</td>
</tr>
<tr>
<td>Benazepril* [ACEI]</td>
<td>Tablets: 5, 10, 20, 40 mg</td>
<td>PO: 0.25–0.5 mg/kg, q12–24h</td>
<td>• Generally start at lower range and increase to maximal dose with monitoring of renal function, serum potassium and BP • Contraindications: dehydration, hyponatremia • Hyperkalemia, azotemia, acute renal failure</td>
</tr>
<tr>
<td>Butorphanol [anxiolytic]</td>
<td>For injection: 2 mg/ml or 10 mg/ml concentrations Tablets: 1, 5, 10 mg</td>
<td>Parenteral: 0.1–0.5 mg/kg, IV/IM/SC PO: 0.5–1.0 mg/kg, q4–6h</td>
<td>• Effects range from “anxiety” to heavy sedation depending on dose • Usual dose for anxiolysis in acute heart failure is 0.1–0.2 mg/kg, IM; repeated in 30 to 60 minutes if needed</td>
</tr>
<tr>
<td>Levo–Carnitine [amino acid]</td>
<td>Tablets/Capsules: 250, 500 mg</td>
<td>PO: 1000–3000 mg per dog q12h</td>
<td>• Do not substitute with racemic mixtures of L- and R-carnitine • See taurine (below)</td>
</tr>
<tr>
<td>Medication</td>
<td>Formulation</td>
<td>Dosage/Route</td>
<td>Indications and Administration Details</td>
</tr>
<tr>
<td>------------</td>
<td>-------------</td>
<td>--------------</td>
<td>----------------------------------------</td>
</tr>
<tr>
<td><strong>Carvedilol</strong>&lt;sup&gt;®&lt;/sup&gt; &lt;br&gt; (beta-blocker, alpha-blocker)</td>
<td>Tablets: 3.125, 6.25, 12.5, 25 mg  &lt;br&gt; Quartering of tablets is difficult due to pill shapes</td>
<td>PO: 0.1–0.5 mg/kg, q12h for cardioprotection in dogs with myocardial failure (e.g. DCM)  &lt;br&gt; PO: 0.1–1.0 mg/kg, q12h for dogs with normal myocardial function</td>
<td>• Gradual up-titration required (weeks to months)  &lt;br&gt; • Beware: precipitation of CHF in dogs with advanced heart disease especially DCM  &lt;br&gt; • Dogs without CHF can tolerate higher initial and target dosages  &lt;br&gt; • Abrupt discontinuation should be avoided, gradual down-titration is recommended  &lt;br&gt; • Myocardial depression, bradycardia (sinus and AVB), hypotension</td>
</tr>
<tr>
<td><strong>Digoxin</strong></td>
<td>Tablets: 0.125, 0.25 mg tablets  &lt;br&gt; Elixirs: 0.05 mg/ml, 0.15 mg/ml</td>
<td>PO: 0.003–0.011 mg/kg, q12h  &lt;br&gt; Note: round the dose down to limit toxicity</td>
<td>• Initial dosages should be at the lower end of the dosing range  &lt;br&gt; • Elixir preparation may be better absorbed – use lower end of dosing range if elixir is used  &lt;br&gt; • Up-titrate based on measurement of serum digoxin levels  &lt;br&gt; • Target serum concentrations (8–12h post pill) to 0.8 to 1.2 ng/ml  &lt;br&gt; • Impaired renal function and hypothyroidism can slow elimination  &lt;br&gt; • Hypokalemia predisposes to toxicosis even at usual dosages  &lt;br&gt; • Inappetence, vomiting, diarrhea (common)  &lt;br&gt; • Bradyarrhythmias, premature complexes, tachyarrhythmias</td>
</tr>
<tr>
<td><strong>Diltiazem</strong> &lt;br&gt; (calcium channel blocker)</td>
<td>For injection: 5 mg/ml (in 5, 10 and 25 ml vials)  &lt;br&gt; Tablets: 30, 60, 90, 120 mg  &lt;br&gt; Sustained release capsules: 60, 120, 180, 240 mg including the Dilacor-XR&lt;sup&gt;®&lt;/sup&gt; formulation (contains four, 60-mg tablets within a 240 mg capsule that is opened)  &lt;br&gt; Cardizem-CD&lt;sup&gt;®&lt;/sup&gt;: 120, 180, 240 mg</td>
<td>Parenteral: 0.05–0.2 mg/kg, IV over 5 minutes; can repeat to cumulative dose of 0.3 mg/kg (then reassess or begin oral therapy)  &lt;br&gt; PO: 2–8 mg/kg, total daily dose, divided q8h (regular diltiazem) or q12h (extended release)</td>
<td>• Cardizem CD&lt;sup&gt;®&lt;/sup&gt; can be reformulated into lower-dose capsules  &lt;br&gt; • Monitor BP with IV administration  &lt;br&gt; • Initial therapy at the lower end of the dosage range  &lt;br&gt; • Up-titration of dose to control rhythm or heart rate  &lt;br&gt; • Dogs without CHF can tolerate higher initial and target dosages  &lt;br&gt; • Hypotension, myocardial depression, AVB</td>
</tr>
<tr>
<td><strong>Dobutamine</strong> &lt;br&gt; (positive inotrope)</td>
<td>For injection (by CRI): Dobutamine 12.5 mg/ml  &lt;br&gt; Must be diluted in 5% dextrose solution or saline solution</td>
<td>Parenteral: 2.5–15 μg/kg/min constant rate intravenous infusion (CRI)</td>
<td>• Do not bolus  &lt;br&gt; • Gradual up–titration to effect  &lt;br&gt; • Increase infusion rate based on a targeted systolic BP and clinical response (increased temperature, improved perfusion)  &lt;br&gt; • Tachycardia, premature complexes, tachyarrhythmias, seizures</td>
</tr>
<tr>
<td><strong>Enalapril</strong>&lt;sup&gt;®&lt;/sup&gt; &lt;br&gt; (ACE-inhibitor)</td>
<td>Tablets: 1 (Veterinary only tablet sizes), 2.5, 5, 10, 20 mg</td>
<td>PO: 0.25–0.5 mg/kg, q12h</td>
<td>• Generally start at lower range and increase to maximal dose with monitoring of renal function, serum potassium and BP  &lt;br&gt; • Contraindications: dehydration, hypotensionemia  &lt;br&gt; • Hyperkalemia, azotemia, acute renal failure</td>
</tr>
</tbody>
</table>
## CEG Formulary: Cardiac Medications for Dogs

**January 2014**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulations</th>
<th>Dosages/Preparations</th>
<th>Side Effects</th>
</tr>
</thead>
</table>
| **Esmolol** [beta-blocker] | For injection: 10 mg/ml, 20 mg/ml as vials or infusion bags                   | Parenteral: 0.05 to 0.2 mg/kg, IV (3-5 minute) bolus 0.025 to 0.1 mg/kg/min, IV-CRI                        | - Rapidly hydrolyzed, short-duration of action, sustained effect requires CRI  
- Monitor heart rate, ECG and BP during administration  
- Do not use in dogs with CHF  
- Dogs with normal ventricular function can tolerate higher dosages  
- Myocardial depression, bradycardia (sinus and AVB), hypotension |
| **Flecainide** [antiarrhythmic] | Tablets: 50, 100, 150 mg Capsule: 200 mg extended release (Tambocor®)          | PO: 1–4 mg/kg, q8 to 12h                                                                                | - Start at the lower end of the dosage range  
- Myocardial depression – use with caution in CHF  
- Proarrhythmia including polymorphic ventricular tachycardia |
| **Furosemide** [loop diuretic] | Veterinary formulations (Salix®): Tablets: 12.5 and 50 mg  
Human formulations: Tablets: 20, 40, 80 mg 1% syrup (10 mg/ml) | Parenteral: 2–4 mg/kg, q1h–6h IV, IM, SC  
Dosing Intervals depend on the response to therapy; initial boluses every 1 to 2 hours; thereafter q4 to 8 hours.  
Constant rate IV infusion: 0.25–1 mg/kg/hour  
PO: 1–6 mg/kg, q8–12h to a maximal total daily dosage of 12 mg/kg, daily | - CRI for treatment of life threatening pulmonary edema is tapered over 12–24h as pulmonary edema and clinical signs resolve  
- Typical initial PO dose in CHF is ≈ 2 mg/kg, q12h  
- Compounded liquids (from tablets) may be better-tolerated than the commercially available 1% (alcohol-based) syrups  
- Polydipsia, polyuria can exacerbate urinary incontinence  
- Azotemia, hypochloremia, hypokalemia, hypomagnesemia, hyponatremia, metabolic alkalosis are common side-effects |
| **Hydralazine** [arterial dilator] | Tablets: 10, 25, 50 mg                                                        | PO: 0.5–3 mg/kg, q12h                                                                                   | - Gradual up titration to effect is required  
- Monitor BP carefully when used for acute afterload reduction  
- In dogs with CHF the first dose should be low (0.5 mg/kg, q12h)  
- In resistant systemic hypertension dosages at the higher range may be needed  
- If used for systemic hypertension, concurrent use of an ACEI is recommended  
- Anorexia, hypotension, reflex tachycardia, activation of the RAAS system, azotemia |
| **Hydrochlorothiazide** [thiazide diuretic] | Tablets: 25, 50 mg                                                            | PO: 1–4 mg/kg, q12–24h                                                                                  | - In dogs receiving furosemide, start with a low dose, q24–48h, evaluate renal function & electrolytes before increasing dose  
- A small (≈25%) reduction in furosemide dosage may limit adverse effects when a hydrochlorothiazide is initiated in chronic CHF  
- Volume depletion, azotemia, acute renal failure, hypokalemia/hyponatremia/hypochloremia are very common |
## CEG Formulary: Cardiac Medications for Dogs

**January 2014**

<table>
<thead>
<tr>
<th>Medication</th>
<th>Formulation</th>
<th>Dosage</th>
<th>Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hydrocodone with homatropine</strong>&lt;br&gt;(cough suppressant)</td>
<td>Tablet: 5 mg hydrocodone (+1.5 mg homatropine per tablet)&lt;br&gt;Syrup: 1 mg/ml concentration (5 mg hydrocodone + 1.5 mg homatropine per 5 ml)</td>
<td>PO: 0.25–1 mg/kg, q6–12h (or PRN)</td>
<td>• Schedule III drug with the potential for human abuse (homatropine added to reduce abuse potential)&lt;br&gt;• Carefully monitor dispensing and prescribing&lt;br&gt;• Start with low dose and titrate up&lt;br&gt;• Sedation, GI upset, constipation</td>
</tr>
<tr>
<td><strong>Lidocaine</strong>&lt;br&gt;[antiarrhythmic]</td>
<td>For injection: 2% lidocaine (20 mg/ml)</td>
<td>Parenteral: 2–4 mg/kg IV to a cumulative dose of 8 mg/kg, over 30 min&lt;br&gt;CRI: 25–75 μg/kg/min</td>
<td>• Initial bolus is typically 2 mg/kg, administered over ≈ 1 minute&lt;br&gt;• IV bolus effects are short-lived; repeated dosing or a CRI may be necessary to maintain rhythm control&lt;br&gt;• Tremors, seizures, vomiting</td>
</tr>
<tr>
<td><strong>Mexiletine</strong>&lt;br&gt;[antiarrhythmic]</td>
<td>Capsule: 150, 200, 250 mg</td>
<td>PO: 4–6 mg/kg, q8h</td>
<td>• Administer at lowest effective dose&lt;br&gt;• Administer with food&lt;br&gt;• Anorexia, vomiting, tremors, idiosyncratic hepatotoxicity</td>
</tr>
<tr>
<td><strong>Nitroglycerine ointment</strong>&lt;br&gt;[vasodilator]</td>
<td>2% paste: 1 inch = 15 mg</td>
<td>Topical administration: 4–12 mg (up to 15 mg in giant breeds) q12h; remove after ≈6h to provide a “nitrate-free interval”</td>
<td>• Delivered dose affected by perfusion of the application area&lt;br&gt;• Apply to hairless / well-perfused skin sites&lt;br&gt;• Duration of administration typically 24 to 48 hours&lt;br&gt;• Hypotension is possible</td>
</tr>
<tr>
<td><strong>Nitroprusside sodium</strong>&lt;br&gt;[vasodilator]</td>
<td>For injection: 25 mg/ml&lt;br&gt;Dilute in 5% dextrose solution and protect solution from light.</td>
<td>Parenteral: 1.25–10 μg/kg/min IV, as a CRI (do not bolus!) with therapy usually limited to 24h duration.</td>
<td>• Continuous monitoring of BP (ideally direct method) advised&lt;br&gt;• In CHF target systolic BP is ≈ 90 mm Hg&lt;br&gt;• Potential for cyanide toxicity with prolonged use (&gt; 48 hrs)&lt;br&gt;• Hypotension, reflex tachycardia, renal failure</td>
</tr>
<tr>
<td><strong>Omega-3 Fatty Acids</strong>&lt;br&gt;[nutraceuticals fish oil]</td>
<td>Docosahexaenoic acid (DHA) and Eicosapentaenoic acid (EPA) combined in a fixed-dose capsule (typically 1.5:1 or 2:1 EPA:DHA)&lt;br&gt;Note: most commercial 1 gm (1000mg) omega 3 capsules contain 180 mg EPA &amp; 120 mg DHA. EPA and DHA are also available as separate capsules.</td>
<td>PO: EPA 40 mg/kg, daily dosage&lt;br&gt;PO: DHA 25 mg/kg, daily dosage&lt;br&gt;PO: combination formulation = 1gm (1000mg) capsule per 5kg body weight, q24 hr</td>
<td>• Gelcaps or soft pills with 180 mg EPA and 120 mg DHA are often appropriately sized for dogs&lt;br&gt;• Avoid products with Vitamin A or D (Vitamin E is a safe additive)&lt;br&gt;• Some dogs do not tolerate / will not ingest fish oils&lt;br&gt;• Gastrointestinal</td>
</tr>
<tr>
<td><strong>Pimobendan</strong>&lt;br&gt;[inodilator]</td>
<td>Chewable (Vetmedin®) tablets: 1.25, 5 mg&lt;br&gt;Capsules (available in some countries outside of USA): 1.25, 2.5, 5 mg</td>
<td>PO: 0.25–0.3 mg/kg, q12h&lt;br&gt;Frequency may be increased to 0.25–0.3 mg/kg, q8h in Stage D CHF</td>
<td>• Do not reformulate into a suspension&lt;br&gt;• Initial dose should be given on an empty stomach if a rapid onset of action is desired&lt;br&gt;• Some dogs do not readily accept the chewable tablet&lt;br&gt;• Potential idiosyncratic side effects (none consistently reported)</td>
</tr>
</tbody>
</table>
### CEG Formulary: Cardiac Medications for Dogs

**January 2014**

<table>
<thead>
<tr>
<th>Medication</th>
<th>Formulation</th>
<th>Dosage and Administration</th>
<th>Side Effects</th>
</tr>
</thead>
</table>
| **Procainamide**    | For injection: 100 mg/ml, 500 mg/ml                                            | Parenteral: 2 mg/kg, slow IV bolus, to a maximum of cumulative dose of 25 mg/kg. 25–40 μg/kg/min CRI 10–20 mg/kg, q4–6h, IM/SQ.  PO: 4-6 mg/kg q 2-4h (regular). PO: 10–20 mg/kg, q 8h (sustained release). | • IV bolus: give 2 mg/kg, over 2–3 minutes to 25 mg/kg.  
• After 8–10 mg/kg, careful monitoring of BP is advised.  
• If bolus therapy effective, can continue as IV-CRI, IM, or SQ.  
• Myocardial depression, vasodilation, hypotension.  
• Proarrhythmia, prolongation of QRS duration & Q–T interval, conduction blocks including AVB.  
• Alteration of hair coat color (chronic). |
| **Sildenafil**       | Tablets: 20, 25, 50, 100 mg (Viagra<sup>®</sup>)                              | PO: 1–3 mg/kg q8–12h                                                                                                     | • Starting dosage is 1 mg/kg PO, q8h or 1–2 mg/kg PO, q12h.  
• Generic formulations and veterinary compounding pharmacies can markedly decrease pill cost (compared to Viagra<sup>®</sup>).  
• Administer with L–arginine 250–500 mg per dog, PO, q12h to enhance effect.  
• Hypotension, abnormal behavior. |
| **Sotalol**         | Tablets: 80, 120, 160, 240 mg                                                 | PO: 1–2.5 mg/kg, q12h                                                                                                    | • Use with caution and at the lower end of dosage range in CHF or DCM or when combined with mexiletine.  
• Dogs without myocardial failure can tolerate higher initial and target doses.  
• Do not combine with other beta–blockers.  
• Myocardial depression, bradyarrhythmia (sinus and AV block), proarrhythmia. |
| **Spironolactone**  | Tablets: 25, 50, 100 mg                                                       | PO: 1–2 mg/kg, q12h or 2 mg/kg, q24h                                                                                    | • Negligible to weak diuretic effect; administered for cardioprotective/anti–fibrotic effects.  
• Higher dosages sometimes used for right-sided CHF.  
• **Hyperkalemia may be exacerbated by co-therapy with an ACEI inhibitor**. |
| **Taurine**         | Tablets/Caplets/Capsules: 250, 500, 1000 mg Powders of various strengths.      | PO: Small dog: 250–500 mg, q12h.  Medium-sized dog: 500 mg, q12h. Large breed dog: 500 – 1000 mg, q12h.          | • Empirical therapy can be administered in suspected deficiency.  
• Deficiency can be confirmed by measuring whole blood/plasma concentrations.  
• Often co-administered with L-carnitine in cases of deficient protein intake (e.g. vegan diet) and DCM in non-traditional breeds and cocker spaniels. |
| **Theophylline**    | Sustained release Tablets/ Capsules: 100, 200, 300, 450 mg                    | PO: 10mg/kg, q12h                                                                                                       | • Starting at lower dosages and up-titrating may limit side effects.  
• Serum concentrations can be measured in human laboratories.  
• Anxiety, hyperactivity, tremors, gastrointestinal signs, tachycardia, polyuria. |
| **Torsemide**  
[loop diuretic] | Tablets: 5, 10, 20 mg | PO: 0.25–0.4 mg/kg, q12–24h |
|-----------------|----------------------|-----------------------------|

- Potent diuretic, generally reserved for advanced (Stage D) CHF
- Typically substituted for one or more daily furosemide doses
- Generally dosed at ≈one-tenth of the furosemide mg dose
- Evaluate renal function and serum electrolytes within a week of initiating torsemide or increasing the dosage
- Hypochloremia, hypokalemia, hypomagnesemia, hyponatremia, azotemia, renal failure

**Note:** This is a CANINE formulary only; typical dosage ranges are shown; clinicians should be familiar with the pharmacology, indications, contraindications, monitoring and toxicity of any drug prescribed. When wide dosage ranges are shown, the clinician should understand potential needs for up-titration of doses as well as potential for cardiac depression and hypotension in dogs with heart failure or impaired ventricular function.

When proprietary names are not indicated, there are usually generic equivalents available.

*These drugs are generally available as a suspension or solution from a compounding pharmacy. Consult with a registered pharmacist regarding stability and storage.

**Drugs not associated with an asterisk should not be reformulated or reconstituted without consultation with a registered pharmacist.**

With the (possible) exception of nitroglycerine ointment, cardiac medications are ineffective when administered topically.

**Abbreviations used in this table:**

- **ACEI** = angiotensin-converting enzyme inhibitor
- **AVB** = atrioventricular block
- **BP** = blood pressure
- **CHF** = congestive heart failure
- **CRI** = constant rate infusion (intravenous)
- **DCM** = dilated cardiomyopathy
- **IM** = intramuscularly
- **IV** = intravenously
- **PDE-V** = phosphodiesterase V
- **PO** = per os (by mouth)
- **q_h** = every __ hours
- **RAAS** = renin-angiotensin-aldosterone system
- **SQ** = subcutaneously